Lately we’ve been getting numerous studies showing that icosapent ethyl is effective and consistent in reducing MACE across a broad range of markers such as TG, LDL-c, Lp(a) and CV Risk Scoring.
This suggests to me that the current labeling for VAZKEPA/VASCEPA is too narrow and because of it’s safety profile should be initiated regardless of baseline TG’s, LDL-c, Lp(a), Risk Scores etc.
Any Doc/Cardio’s out there want to chime in?
News 
Market Data 
Discover 
